HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Summer In Sight, FDA Pushes Final Sunscreen Rule To Fall

This article was originally published in The Rose Sheet

Executive Summary

FDA aims to issue a final OTC monograph for sunscreens in October, according to the Department of Health and Human Services' semi-annual regulatory agenda published April 26
Advertisement

Related Content

FDA still plugging away on sunscreen rule
FDA still plugging away on sunscreen rule
Environmental Group Assesses Availability Of UVA Protection, Warns Public
Skin Cancer Foundation Adds UVA Requirements To Seal Standards
EWG Advises Against Vitamin A Compound, More Than 90% Of Sunscreens
Sunscreen Brands Reach Out To Consumers For Skin Cancer Awareness Month
EWG pushing again for final sunscreen monograph
Dermatologists Expect FDA Sunscreen Rule "Soon," End Product Seal Program
Industry, Docs And Congress Combine Voices In Call For Final Sunscreen Regs
Industry Groups Burned About Proposed Sunscreen Labeling Requirements
Advertisement
UsernamePublicRestriction

Register

RS016906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel